{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:00:38Z","timestamp":1785261638405,"version":"3.55.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Thrombosis Research Institute (TRI), London, UK and Anthos Therapeutics - a Novartis Company (Boston, USA). TRI and Anthos Therapeutics were involved in study design and the decision to publish."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>GARDENIA is a global, multicentre, prospective, non-interventional study in high-risk atrial fibrillation (AF) patients, who were untreated with anticoagulants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Provide contemporary evidence on reasons for non-treatment with an anticoagulant, and outcomes in high-risk AF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      GARDENIA enrolled 704 AF patients with a CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VA score \u22652 and an elevated risk of bleeding (older age (\u226570 years), reduced renal function, concomitant antiplatelet or NSAID use, or other conditions associated with increased bleeding risk), and had not been recently treated with an oral anticoagulant (OAC). Patients were followed for at least 4 months. The two-year risks of mortality, stroke and major bleeding with or without direct OACs (DOACs) in these patients was estimated using the GARFIELD risk score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>History of major bleeding (18.7%), physician-assessed high-risk of bleeding (17.1%), and patient refusal (17.6%) were the top reasons for not initiating OACs. The 100-person-year event rates (95% CI) for mortality, stroke\/systemic embolism (SE)\/transient ischemic attack (TIA), and ISTH major bleeding were 13.22 (10.33, 16.92), 2.12 (1.14, 3.94), and 2.21 (1.13, 3.91), respectively. GARFIELD risk analysis indicated a 31% and 40% increase in the risk of mortality and stroke, respectively, and a\u2009~\u200930% decrease in risk of major bleeding, compared to the estimated risk, had the patients been anticoagulated. The study was prematurely terminated due to low rate of patient accrual.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Perceived risk of bleeding was the leading cause for non-treatment with OACs in high-risk AF patients. Risk prediction modelling indicated that the benefits of anticoagulation in stroke and mortality reduction outweigh the risk of bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354382","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:24:33Z","timestamp":1785259473000},"page":"e0354382","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-2704","authenticated-orcid":true,"given":"A.K.","family":"Kakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Hug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janeen","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Freedholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanobar","family":"Parkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Virdone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8575-0963","authenticated-orcid":true,"given":"Herman Sandeep","family":"Prakasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Fluharty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-2752","authenticated-orcid":true,"given":"Keith A. A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the GARDENIA investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"40","key":"pone.0354382.ref001","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","article-title":"Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"European Heart Journal"},{"issue":"8","key":"pone.0354382.ref002","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac192","article-title":"Epidemiology and impact of frailty in patients with atrial fibrillation in Europe","volume":"51","author":"M Proietti","year":"2022","journal-title":"Age Ageing"},{"issue":"12","key":"pone.0354382.ref003","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1055\/s-0042-1756355","article-title":"Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III","volume":"122","author":"GF Romiti","year":"2022","journal-title":"Thromb Haemost"},{"issue":"9","key":"pone.0354382.ref004","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/europace\/euac004","article-title":"Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis","volume":"24","author":"I Diemberger","year":"2022","journal-title":"Europace"},{"issue":"4","key":"pone.0354382.ref005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/02813432.2014.984952","article-title":"Characterization of patients with atrial fibrillation not treated with oral anticoagulants","volume":"32","author":"C Johansson","year":"2014","journal-title":"Scand J Prim Health Care"},{"issue":"2","key":"pone.0354382.ref006","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/STROKEAHA.123.044407","article-title":"Net Clinical Benefit of Oral Anticoagulation Among Frail Patients With Atrial Fibrillation: Nationwide Cohort Study","volume":"55","author":"M S\u00f8gaard","year":"2024","journal-title":"Stroke"},{"key":"pone.0354382.ref007","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.tru.2021.100053","article-title":"Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation","volume":"4","author":"M Paquette","year":"2021","journal-title":"Thrombosis Update"},{"issue":"12","key":"pone.0354382.ref008","doi-asserted-by":"crossref","first-page":"108081","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.108081","article-title":"Trends over time in oral anticoagulation and stroke rates in atrial fibrillation: A community-based study","volume":"33","author":"BA Williams","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"22","key":"pone.0354382.ref009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"AM Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"pone.0354382.ref010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2023.10.013","article-title":"Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia","volume":"232","author":"N Al-Hussainy","year":"2023","journal-title":"Thromb Res"},{"issue":"22","key":"pone.0354382.ref011","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0354382.ref012","first-page":"279","article-title":"Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial","volume":"149","author":"LPT Joosten","year":"2024","journal-title":"Circulation"},{"issue":"20","key":"pone.0354382.ref013","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"C Held","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0354382.ref014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry","volume":"1","author":"JC Hsu","year":"2016","journal-title":"JAMA Cardiol"},{"key":"pone.0354382.ref015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2020.12.062","article-title":"Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"144","author":"A Sugrue","year":"2021","journal-title":"Am J Cardiol"},{"issue":"8","key":"pone.0354382.ref016","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2021.1232","article-title":"Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA2DS2-VASc Factors","volume":"6","author":"H Abdel-Qadir","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"4","key":"pone.0354382.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"GJ Hankey","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0354382.ref018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.03.082","article-title":"CO8 Design and Rationale of a Global Prospective Observational Study of Real-World Management of Patients with Atrial Fibrillation at High Risk of Stroke- Gardenia","volume":"26","author":"A Kakkar","year":"2023","journal-title":"Value in Health"},{"issue":"2","key":"pone.0354382.ref019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/ehjqcco\/qcab028","article-title":"GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation","volume":"8","author":"KAA Fox","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"pone.0354382.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.09.011","article-title":"International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)","volume":"163","author":"AK Kakkar","year":"2012","journal-title":"Am Heart J"},{"issue":"1","key":"pone.0354382.ref021","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"12","key":"pone.0354382.ref022","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"L Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"5","key":"pone.0354382.ref023","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"2","key":"pone.0354382.ref024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgs.14688","article-title":"Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke","volume":"65","author":"ER McGrath","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"18","key":"pone.0354382.ref025","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"K Okumura","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0354382.ref026","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"D Ko","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"pone.0354382.ref027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/03007995.2021.1982684","article-title":"The burden of undertreatment and non-treatment among patients with non-valvular atrial fibrillation and elevated stroke risk: a systematic review","volume":"38","author":"M Sussman","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"9921","key":"pone.0354382.ref028","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"CT Ruff","year":"2014","journal-title":"Lancet"},{"key":"pone.0354382.ref029","doi-asserted-by":"crossref","first-page":"1756284821997352","DOI":"10.1177\/1756284821997352","article-title":"Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients","volume":"14","author":"S Deitelzweig","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"issue":"4","key":"pone.0354382.ref030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9638","article-title":"Patients and Their Physician\u2019s Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation Not Receiving an Anticoagulant","volume":"6","author":"CP Cannon","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"25","key":"pone.0354382.ref031","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/CIRCULATIONAHA.114.014343","article-title":"Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study","volume":"131","author":"E Svennberg","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"pone.0354382.ref032","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"JA Joglar","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"pone.0354382.ref033","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/europace\/euz292","article-title":"The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events","volume":"22","author":"D Atar","year":"2020","journal-title":"Europace"},{"issue":"3","key":"pone.0354382.ref034","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamacardio.2016.0529","article-title":"Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry","volume":"1","author":"JP Piccini","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"20","key":"pone.0354382.ref035","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1161\/CIRCULATIONAHA.125.074100","article-title":"Factor XI inhibition for atrial fibrillation: where do we stand?","volume":"151","author":"SM Patel","year":"2025","journal-title":"Circulation"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:24:45Z","timestamp":1785259485000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354382"}},"subtitle":[],"editor":[{"given":"Ufuk","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354382","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}